Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ICP-248 in relapsed or refractory mantle cell lymphoma
CTR20252301Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mesutoclax in mantle cell lymphoma (MCL), sponsored by Innovent Biologics. Started Aug 2025; status: active.
02
Drugs
mesutoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20252301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252301.